Literature DB >> 12794628

The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial.

Thomas A Holly1, Aaron Satran, David S Bromet, Jennifer H Mieres, Martin J Frey, Michael D Elliott, Gary V Heller, Robert C Hendel.   

Abstract

BACKGROUND: Failure to achieve an adequate heart rate limits the sensitivity of exercise myocardial perfusion imaging (MPI) for the detection of coronary artery disease. In addition, it is often not possible to discontinue medications that may blunt the heart rate response to exercise, because of conditions such as hypertension or angina. However, if pharmacologic stress testing is performed, the ability to assess functional capacity is lost. Accordingly, we developed a protocol that incorporates adenosine stress with symptom-limited exercise. METHODS AND
RESULTS: As part of a multicenter study, 35 patients were enrolled prospectively and underwent both exercise MPI and exercise MPI with a 4-minute adenosine infusion on a separate day. Technetium 99m sestamibi was injected at or near peak exercise (exercise only) and at 2 minutes into the adenosine infusion (combined exercise and adenosine). The perfusion images were interpreted in a blinded fashion. The combined adenosine and exercise protocol was well tolerated. The summed stress scores and summed difference scores were greater in the exercise-plus-adenosine group than in the exercise-only group (10.0 vs 8.5, P =.02, and 4.9 vs 3.3, P =.002, respectively). Exercise time was slightly but significantly less with the exercise-plus-adenosine protocol (8 minutes 46 seconds vs 8 minutes 11 seconds, P =.027).
CONCLUSION: A protocol combining 4 minutes of adenosine infusion with symptom-limited exercise was safe and well tolerated. Furthermore, this protocol resulted in a greater amount of myocardial ischemia detected on MPI while allowing for the assessment of functional capacity. A combined exercise and adenosine protocol may be a useful test for patients undergoing MPI who are unlikely to achieve an adequate chronotropic response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794628     DOI: 10.1016/s1071-3581(02)43236-9

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  17 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

Review 2.  Prognostic value of thallium-201 myocardial perfusion imaging. A diagnostic tool comes of age.

Authors:  K A Brown
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

3.  Impact of antianginal medications, peak heart rate and stress level on the prognostic value of a normal exercise myocardial perfusion imaging study.

Authors:  K A Brown; M Rowen
Journal:  J Nucl Med       Date:  1993-09       Impact factor: 10.057

4.  Pharmacologic stress perfusion imaging with adenosine: role of simultaneous low-level treadmill exercise.

Authors:  Habib Samady; Frans J Th Wackers; Tammy M Joska; Barry L Zaret; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

5.  Impact of an abbreviated adenosine protocol incorporating adjunctive treadmill exercise on adverse effects and image quality in patients undergoing stress myocardial perfusion imaging.

Authors:  M D Elliott; T A Holly; S M Leonard; R C Hendel
Journal:  J Nucl Cardiol       Date:  2000 Nov-Dec       Impact factor: 5.952

6.  Complications of exercise and pharmacologic stress tests: differences in younger and elderly patients.

Authors:  A Hashimoto; E L Palmar; J A Scott; S A Abraham; A J Fischman; T L Force; J B Newell; C A Rabito; G D Zervos; T Yasuda
Journal:  J Nucl Cardiol       Date:  1999 Nov-Dec       Impact factor: 5.952

7.  Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry.

Authors:  M D Cerqueira; M S Verani; M Schwaiger; J Heo; A S Iskandrian
Journal:  J Am Coll Cardiol       Date:  1994-02       Impact factor: 24.094

8.  Influence of exercise intensity on the presence, distribution, and size of thallium-201 defects.

Authors:  G V Heller; I Ahmed; P L Tilkemeier; M M Barbour; C E Garber
Journal:  Am Heart J       Date:  1992-04       Impact factor: 4.749

Review 9.  Dipyridamole cardiac imaging.

Authors:  A S Iskandrian; J Heo; A Askenase; B L Segal; N Auerbach
Journal:  Am Heart J       Date:  1988-02       Impact factor: 4.749

10.  Safety and clinical utility of combined intravenous dipyridamole/symptom-limited exercise stress test with thallium-201 imaging in patients with known or suspected coronary artery disease.

Authors:  A P Ignaszewski; L X McCormick; P G Heslip; A J McEwan; D P Humen
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

View more
  16 in total

1.  A helping hand for regadenoson tests.

Authors:  Preeti Kansal; Thomas A Holly
Journal:  J Nucl Cardiol       Date:  2015-10-22       Impact factor: 5.952

2.  Stress protocols and tracers.

Authors:  Milena J Henzlova; Manuel D Cerqueira; John J Mahmarian; Siu-Sun Yao
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

Review 3.  Pharmacologic stress myocardial perfusion imaging: a practical approach.

Authors:  Michael I Miyamoto; Sharon L Vernotico; Haresh Majmundar; Gregory S Thomas
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

4.  Should PET replace SPECT for evaluating CAD? The end of the beginning.

Authors:  Marcelo F Di Carli; Rory Hachamovitch
Journal:  J Nucl Cardiol       Date:  2006 Jan-Feb       Impact factor: 5.952

5.  Symptom-limited exercise combined with dipyridamole stress: prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT imaging.

Authors:  Alan W Ahlberg; Sarkis B Baghdasarian; Haris Athar; Jeffrey P Thompsen; Deborah M Katten; Gavin L Noble; Igor Mamkin; Anuj R Shah; Ivette A Leka; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

Review 6.  The emerging role of the selective A2A agonist in pharmacologic stress testing.

Authors:  Anthony S Gemignani; Brian G Abbott
Journal:  J Nucl Cardiol       Date:  2010-06       Impact factor: 5.952

7.  Off-label, but on-target: use of regadenoson with exercise.

Authors:  Robert C Hendel; Lauren Frost
Journal:  J Nucl Cardiol       Date:  2013-04       Impact factor: 5.952

8.  Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.

Authors:  Randall C Thompson; Harshal Patil; Elaine C Thompson; Gregory S Thomas; Mohammed Al-Amoodi; Kevin F Kennedy; Kevin A Bybee; A Iain McGhie; James H O'Keefe; Lisa Oakes; Timothy M Bateman
Journal:  J Nucl Cardiol       Date:  2012-12-12       Impact factor: 5.952

9.  Does risk for major adverse cardiac events in patients undergoing vasodilator stress with adjunctive exercise differ from patients undergoing either standard exercise or vasodilator stress with myocardial perfusion imaging?

Authors:  Sanjeev U Nair; Alan W Ahlberg; Deborah M Katten; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2014-08-15       Impact factor: 5.952

10.  Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.

Authors:  M I Ross; E Wu; J T Wilkins; D Gupta; S Shen; D Aulwes; K Montero; T A Holly
Journal:  J Nucl Cardiol       Date:  2013-02-13       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.